Genetic deficiency of dystrophin leads to disability and premature death in
INTRODUCTION
Absence of dystrophin in Duchenne muscular dystrophy (DMD) leads to membrane fragility and secondary damage to muscle (both skeletal and cardiac)(1). Early disability is due predominantly to the skeletal myopathy, but heart failure is the most common cause of death (2) . Cardiospherederived cells (CDCs) may represent a viable therapeutic option (3) (4) (5) . CDCs are progenitor cells intrinsic to the heart; in clinical trials after myocardial infarction, CDCs promote cardiomyogenesis and reverse established scar (6, 7) . Multiple lines of evidence now indicate that most of the beneficial effects of CDCs are indirect. In the extreme, allogeneic CDCs are cleared completely within several weeks, but their functional and structural benefits persist at least 6 months (8) . CDCs secrete diffusible factors that promote angiogenesis, recruit endogenous progenitor cells, and coax surviving heart cells to proliferate (9, 10) ; transplanted CDCs suppress maladaptive remodeling (11) , apoptosis (10, 12) , fibrosis (13) , and inflammation after myocardial infarction (13) and in nonischemic cardiomyopathy (14) . These diverse mechanisms appear to be mediated via the secretion of exosomes laden with noncoding RNA including microRNAs (miRs) (15) , consistent with the notion that exosomes contain a plethora of bioactive molecules which target multiple signaling pathways synergistically (16) . In a murine model of myocardial infarction, CDC-secreted exosomes (CDC-exosomes) mimic the functional and structural benefits of CDCs, while blockade of exosome biosynthesis renders CDCs ineffective (15) . Given the clinical data with CDCs, and the complementarity between their therapeutic actions and the pathophysiological processes underlying Duchenne cardiomyopathy (oxidative stress (17, 18) , inflammation (19), fibrosis (20), and mitochondrial dysfunction (21)), we reasoned that CDCs and their exosomes might be useful in treating Duchenne cardiomyopathy. Our early work reported in abstract form (22, 23) revealed striking phenotypic correction by CDCs in mdx dystrophic mice, motivating the ongoing HOPE-Duchenne clinical trial (24) of CDCs in DMD patients. Initially, we had not aspired to restore skeletal muscle function, but merely to offset the pathophysiological consequences of dystrophin deletion in the heart. We now report that CDCs and their secreted exosomes potently improve skeletal muscle structure and function, contributing to major systemic benefits after injection of CDCs into the heart.
RESULTS

CDC transplantation in mdx hearts
Intramyocardial injection of first and second (lower) doses of CDCs into the hearts of mdx mice improved left ventricular function (as manifested by ejection fraction [EF]) and volumes, relative
to placebo, for at least 6 months ( Fig. 1A and fig. S1A ). The CDC-induced improvement in EF persisted beyond the point at which no surviving CDCs were detectable in mdx hearts (3 weeks after CDC delivery; fig. S1B ). In addition to improving EF, CDC injection enhanced ambulatory function (Fig. 1B) . Ten-month-old wild-type mice (WT) and mdx mice (distinct from the mdx mice studied in Fig. 1A ) were subjected to weekly high-intensity treadmill exercise, starting 3 weeks after single-dose CDC or vehicle administration. CDC-treated mdx mice showed a substantial increase in maximal exercise capacity, relative to vehicle-treated mdx mice, over the 3 mos that exercise capacity was measured; survival also differed in the two groups (Fig. 1C) . By ~23 mos of age, all vehicle-treated mdx mice had died, whereas >50% of CDC-treated mdx mice remained alive (Fig. 1C) . In investigating mechanism, we first studied known (anti-oxidative, antiinflammatory, anti-fibrotic, and cardiomyogenic) effects of CDCs (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Injection of CDCs led to major changes in the expression of genes related to oxidative stress, inflammation and mitochondrial integrity ( fig. S2 ). The Nrf2 anti-oxidant pathway was activated in CDC-treated mdx heart (Fig. 1D ). Nrf2 is normally repressed by Keap1, but oxidative stress (as well as Nrf2 phosphorylation by protein kinases such as Akt) causes dissociation of the Nrf2-Keap1 complex, culminating in nuclear translocation of Nrf2 and transcriptional activation of antioxidant enzymes (25). In mdx hearts, levels of phosphorylated Akt (Fig. 1E ), total Nrf2 ( Fig. 1F ) and nuclear Nrf2 ( Mitochondrial structure and function are abnormal in muscular dystrophy-associated heart failure (21). Whole-transcriptome analysis revealed major changes in the expression of genes related to mitochondrial integrity in mdx hearts ( fig. S2B ). Consistent with this finding, CDCs restored mitochondrial ultrastructure (Fig. 1L) , increased mitochondrial DNA copy numbers (but not mitochondrial number; fig. S6 ), augmented levels of respiratory chain subunits ( Fig. 1M ) and normalized the deficient respiratory capacity of isolated mdx mitochondria (Fig. 1N ). Of note, the salutary mitochondrial changes were associated with upregulation of antioxidant enzymes and reductions of oxidative stress and inflammation (Figs. 1D-k; figs. S2C-E, S5). We also probed the effects of CDCs on cardiomyogenesis. Vehicle-treated mdx hearts exhibited a modest increase in the numbers of cycling (Ki67 + ) and proliferating (aurora B + ) cardiomyocytes ( fig. S7 ), presumably as a compensation for ongoing cardiomyocyte loss. CDCs are known to increase endogenous cardiomyogenesis in ischemic (7, 11, 12, 27, 28 ) and non-ischemic models (14) . Similar effects were seen in the mdx heart: CDC treatment promoted cardiomyocyte cycling and proliferation, as evidenced by a marked increase in Ki67 + and aurora B + cardiomyocytes ( fig. S7 ).
CDC-exosome transplantation in mdx hearts
CDC-exosomes mimic the functional and structural benefits of CDCs in a murine model of myocardial infarction (15) . In mdx mice, likewise, exosomes, isolated from media conditioned by cardiomyocytes increased in CDC-exosome-injected mdx hearts. The effects of CDC-exosomes were mediated at least in part via clathrin-mediated endocytosis by the surrounding myocardium ( fig. S8D ).
Remote effects of CDC transplantation in mdx heart
Intramyocardial injection of CDCs and their exosomes improved Duchenne cardiomyopathy, reversing key pathophysiological processes in the mdx mouse heart (Figs. 1, 2 ). These changes were associated with a substantial increase in exercise capacity, which was disproportionate to the improvement in cardiac function: EF increased by <10% (Fig. 1A) , while ambulatory capacity doubled (Fig. 1B) (Fig. 3L ).
As a basis for the remote effects of intramyocardial injection of CDCs on skeletal muscle, we considered the possibility that exosomes secreted by CDCs lodged in the heart might exit in the venous effluent and exert remote signaling. Principal components analysis revealed that CDCexosomes were very similar in their RNA contents to the exosomes isolated from effluents of isolated CDC-treated mdx hearts, but quite distinct from exosomes in the effluents of vehicle-treated mdx hearts 3 days after intramyocardial CDC injection (Fig. 3M) 
Systemic CDC-exosome injection
To further evaluate the potential of exosomes to mediate systemic benefits, we injected CDCexosomes into the left ventricular cavity of mdx hearts. Six hours post-injection, fluorescentlylabeled CDC-exosomes were evident not only in the heart and skeletal muscle ( 
CDC-exosome injection into mdx skeletal muscle
To investigate primary effects on skeletal muscle, we injected CDC-exosomes directly into the soleus in mdx mice. Histological analysis revealed a paucity of surviving myofibers in vehicleinjected mdx soleus relative to wild-type controls, and those that remained were hypertrophic (Fig.   5A ). CDC-exosomes markedly increased the total number of myofibers and shifted the size distribution to smaller diameters, indicative of myofiber proliferation 3 weeks after injection (Fig.   5B ). Consistent with this interpretation, the number of MyoD + cells was augmented after CDCexosome injection (Figs. 5A,C), with increased tissue levels of MyoD and myogenin, the major transcription factors orchestrating myoblast determination and differentiation, respectively (29) (Fig. 5D ). In physiological muscle growth, IGF-1 is commonly implicated as an upstream signal (30), but the effects of CDC-exosomes on mdx soleus muscle were independent of IGF-1 receptors (Fig. 5E ). Along with enhanced muscle regeneration, intrasoleus CDC-exosome injection decreased inflammation (Fig. 5F ) and fibrosis (Fig. 5G) . The net effect was complete restoration of contractile force in soleus muscles injected with CDC-exosomes (Fig. 5H ).
CDC-exosomes in human Duchenne cardiomyocytes derived from iPS cells
Demonstration of efficacy in multiple models of DMD would bolster the notion that CDCexosomes may be viable therapeutic candidates. Duchenne human induced pluripotent stem cell (iPS)-derived cardiomyocytes (DMD CMs) exhibit a number of phenotypic deficits characteristic of DMD, including decreased oxygen consumption rate (OCR) reminiscent of that observed in mdx heart mitochondria ( Fig. 1N) , and abnormal calcium cycling (31). Priming DMD CMs with CDC-exosomes one week earlier suppressed beat-to-beat calcium transient alternans during 1Hz burst pacing (a measure of arrhythmogenicity (32); Fig. 6A ) and normalized OCR (Fig. 6B ). The congruence of experimental findings in the two DMD models is noteworthy: the mdx mouse has a nonsense mutation in exon 23 of the murine dystrophin gene, while the DMD patient whose iPS cells were studied here has a fundamentally different genetic lesion in the human dystrophin gene (exon 50 deletion with frame shift (31)). Thus, CDC-exosomes exert salutary effects in at least two classes of DMD mutations.
DISCUSSION
We propose that CDCs act by secreting exosomes which are taken up by surrounding myocardium and by skeletal muscle, antagonizing multiple pathophysiological pathways that underlie DMD.
The congruent effects in mdx mice and in exon 50-deleted DMD hCM (Fig. 6 ) highlight the ability of CDC-exosomes to benefit multiple disease-causing dystrophin mutations. In the present work, we have not excluded the possibility that CDCs and their exosomes might, unexpectedly, increase dystrophin expression. We are presently investigating that possibility. Nevertheless, the dystrophin-independent actions of CDCs and their exosomal contents should be generalizable.
After all, CDCs and their exosomes work quite well in cardiomyopathies not associated with dystrophin deficiency (7, 14, 27) . The protean actions of CDCs and their exosomes include improved mitochondrial function, enhanced myocyte proliferation, and suppression of oxidative stress, inflammation and fibrosis (Fig. 7) . Observed effects which appear to be independent of dystrophin restoration include the suppression of inflammation in mdx liver (an organ with no dystrophin expression). Notably, CDCs and their exosomes not only reverse the dystrophic phenotype but also forestall progression: the functional benefits of cardiac injections of CDCs or their exosomes persist for at least 3 months, and single doses of CDCs decrease mortality more than one year later in mdx mice. These findings beg the investigation of exosomally-triggered epigenomic modifications as a potential basis for the durable benefits (33), but such experiments are beyond the scope of this report.
The ongoing HOPE-Duchenne trial is designed to assess single-dose delivery of CDCs to the heart (24). Whether in this first trial or in follow-up studies, our results give reason to wonder if CDCs will turn out to benefit not only the cardiomyopathy but also the skeletal myopathy of DMD.
Exosomes derived from CDCs are promising next-generation therapeutic candidates with mechanisms of action fundamentally different to those currently in active development for DMD (e.g., exon skipping or myoediting).
Methods
Please see supplement for expanded methods.
Animal study:
We studied mdx mouse model of DMD (C57BL/10ScSn-Dmdmdx/J) and wild-type strainmatched mouse (C57BL/10ScSnJ wild type mouse heart) (Jackson Laboratory, USA) from 10 months of age. To optimize the process of CDC transplantation, preliminary dose-response experiments were performed, which identified 1x10 5 was used to isolate exosomes from conditioned media after sequential centrifugations at 300g (10min) and 10,000g (30min) and filtration with 0.22 micron filters(36). Isolated exosomes were re-suspended in PBS (for in vivo and in vitro experiments) and the ratio of exosome to protein was measured using Nanosight particle counter (37) 
Echocardiography
Echocardiographic studies were performed two days before (Baseline) and 3 weeks, 2 and 3 months after first CDC/CDC-exosome (CDC-exosome) or vehicle injection and 3 weeks, 2 and 3 months after second CDC/CDC-exosome or vehicle injection (when applicable) using the Vevo 770 Imaging System (VisualSonics, Toronto, Canada)(4). The same imaging system was used to perform echocardiographic studies at baseline (2 days before) and 3 weeks after selected RNA (or control) injection. After induction of light general anesthesia, the heart was imaged at the level of the greatest LV diameter. LV ejection fraction (LVEF) was measured with VisualSonics version 1.3.8 software from 2-dimensional long-axis views.
Treadmill exercise testing and survival analysis
For Fig. 1B , exercise capacity was assessed weekly with Exer-3/6 open treadmill (Columbus Instruments, Columbus, OH), beginning 1 week pre-operatively and 3 weeks after CDC/vehicle injection (exercise capacity measured in a subset of mdx mice 1 week pre-operatively was equivalent to that measured 3 weeks post-operatively in the Mdx+Vehicle group). After an acclimation period (10 m/min for 20 min), stepwise increases in average speed (2 m/min) were applied every two minutes during treadmill exercise until the mouse became exhausted (spending >10 seconds on shocker; continuous nudging was used during treadmill to help mice stay on the track). Subsequently, the mouse was returned to the cage and the total distance recorded. The treadmill protocol conformed to guidelines from the American Physiological Society(40). After 3 months of weekly exercise, CDC/vehicle mdx mice along with wild-type age-matched mice were followed for assessment of mortality (Fig. 1C) .
In vitro isometric contractile properties of skeletal muscle
Mice were deeply anesthetized with Ketamine/Xylazine (80 mg/kg and 10 mg/kg body weight IP), the soleus (SOL) and/or extensor digitorum longus (EDL) and/or diaphragm (DIA) muscles were rapidly excised, and the animal was euthanized. Briefly, following a lateral midline skin incision of the lower leg the SOL and/or EDL muscle was dissected and isolated and its tendons of origin and insertion were tightened with silk suture (3-0) and rapidly excised. The SOL or EDL muscle was vertically mounted in a tissue bath containing a mammalian Ringer's solution of the following composition: (in mM) 137 NaCl, 5 KCl, 2 CaCl2, 1 MgSO4, 1 NaH2PO4, 24 NaHCO3, 11 glucose.
The solution was constantly aerated with 95% O2 and 5% CO2 with pH maintained at 7.35 and temperature kept at 24°C. For studies of the diaphragm, following a left costal margin skin and muscle incision, a section of the midcostal hemidiaphragm was transferred to a preparatory Sylgarlined dish containing cold Ringer's and a narrow 3-4 mm wide strip of diaphragm was isolated maintaining fiber attachments to the rib and central tendon intact which were tighten with silk suture and mounted vertically in the tissue bath. One end of the SOL, EDL or DIA was secured to a clamp at the bottom of the dish and one end was attached to a calibrated force transducer (Cambridge Technology Model 300B, Watertown, MA). A micromanipulator linked to the system was used to adjust muscle length. Platinum plate electrodes placed on each side of the muscle were used for direct muscle stimulation (Grass Model S88 stimulator; Quincy, MA) using 0.2 msec duration monophasic rectangular pulses of constant current delivered at supramaximal intensity.
Muscle length was adjusted until maximum isometric twitch force responses were obtained.
Isometric contractile properties were determined at optimal length (Lo). Peak twitch force (Pt) was determined from a series of single pulses. Force/frequency relationships were measured at stimulus frequencies ranging from 5-150 pulses per second (pps). The stimuli were presented in trains of 1 sec duration with an interval of at least 1 min intervening between each stimulus train. Muscle forces generated, including Pt and maximum tetanic force (Po), were normalized for the estimated physiological cross-sectional areas (CSA) of the muscle segment (CSA = muscle weight/1.056 x Lo; where 1.056 g/cm 3 represents the density of muscle) and expressed in Newtons (N)/cm 2 . For the SOL and EDL muscle Lo was also normalized for muscle fiber length (0.71 and 0.44 of Lo, respectively) in estimating muscle specific force. Absolute muscle forces generated by the SOL and EDL are also reported (mN)(41).
iPSC derived cardiomyocytes
Urine-derived cells were seeded onto Matrigel (BD, San Jose, California) coated 12 well plates at 50,000 cells/well and allowed to attach overnight (day 0). On day two, cells were transduced with high-titer OSKM viral supernatants in the presence of 8 μg/ml polybrene for three hours. Viral supernatants were replaced with fresh USC medium and after three days, replaced with mTeSR1 medium (StemCell Technology, Vancouver, BC) and changed daily. As iPSC-like colonies appeared over time, they were picked using glass pasteur pipettes under a stereo dissection and IκB-α were normalized to total Akt, Nrf2 and IκB-α. Western blot analyses of collagen I and collagen III were conducted under non-reducing, non-denaturing conditions.
Statistical analysis
All pooled data are presented as mean±SEM, except results for alternans data (Fig. 6A ) which are presented as mean ±SD. Normality and equality of variances of data sets were first tested using Kolmogorov-Smirnov and Levene's tests, respectively. If both were confirmed, t-test or analysis of variance followed by Bonferroni's post hoc test were used for determination of statistical significance; if either normality or equality of variances was not assured, nonparametric tests (Wilcoxon test or Kruskal-Wallis test followed by Dunn's post-test) were applied (SPSS II, SPSS Inc., Chicago, Illinois). No preliminary data were available for a power analysis. Results from a pilot project allowed us to power subsequent studies. The study followed preclinical reporting standards, as described (42). Age-matched mice were randomly allocated to experimental groups using computer generated randomization schedules (https://www.randomizer.org). Conduct of experiments and analysis of results and outcomes were performed in a blinded manner (allocation concealment and blinded assessment of outcome). There was no post-hoc exclusion of mice or data after the analysis before unblinding.
Ejection Fraction Data
Preliminary data were collected from a pilot study of 5 animals per group measuring ejection fraction at baseline, and again 3 weeks after treatment with cells or vehicle control in mdx and corresponding wild-type mice (C57BL/10ScSnJ; Suppl. Table 2 
Treadmill Data
Preliminary data were collected from a pilot study of 5 animals per group measuring treadmill distance (i.e., the distance ambulated before exhaustion, as described below) at baseline, and again 3 weeks after treatment with cells or vehicle control in mdx animals and corresponding wild-type animals (Suppl. Table 2 ). The measured treatment effect was approximately 150 meters, with limited differences observed over time in untreated groups. Group standard deviations were approximately 75 meters, with more variation observed after treatment. We anticipated larger differences between groups over later time points with possible increase in measured variance.
Therefore, with 11 animals per treatment group in the each of the transgenic groups, and 7 wildtype control animals, the study had at least 80% power to detect a difference of 100 meters or greater in treatment effect and changes of at least 30 meters over time in a study design with 12 measurements per animal over time assuming a compound symmetry covariance structure, a correlation of 0.7 between measurements within animals over time, and a two-sided alpha of 0.05.
(Power computed via PASS v. 11.0.). 
